Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNeuropharmacology

The unique α4(+)/(-)α4 agonist binding site in (α4)3(β)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology vs. the (α4)2(β2)3 subtype

J. Brek Eaton, Linda M. Lucero, Harrison Stratton, Yongchang Chang, John F. Cooper, Jon M. Lindstrom, Ronald J. Lukas and Paul Whiteaker
Journal of Pharmacology and Experimental Therapeutics November 4, 2013, jpet.113.208389; DOI: https://doi.org/10.1124/jpet.113.208389
J. Brek Eaton
1 Barrow Neurological Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda M. Lucero
1 Barrow Neurological Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harrison Stratton
1 Barrow Neurological Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongchang Chang
1 Barrow Neurological Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John F. Cooper
2 University of Pennsylvania;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jon M. Lindstrom
3 University of Pennsylvania Medical School
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald J. Lukas
1 Barrow Neurological Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Whiteaker
1 Barrow Neurological Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Selected nicotinic agonists were used to activate and desensitize high-sensitivity (HS; (α4)2(β2)3) or low-sensitivity (LS; (α4)3(β2)2) isoforms of human α4β2-nicotinic acetylcholine receptors (nAChR). Function was assessed using 86Rb+ efflux in a stably-transfected SH-EP1-hα4β2 human epithelial cell line, and two-electrode voltage-clamp electrophysiology in Xenopus oocytes expressing concatenated pentameric HS or LS α4β2-nAChR constructs (HSP and LSP). Unlike previously-studied agonists, desensitization bythe highly-selective agonists A-85380 and sazetidine-A (Saz-A) preferentially reduced α4β2-nAChR HS-phase vs. LS-phase responses. The concatenated-nAChR experiments confirmed that ≈20% of LS-isoform ACh-induced function occurs in an HS-like phase, which is abolished by Saz-A preincubation. Six mutant LSP were generated, each targeting a conserved agonist-binding residue within the LS-isoform-only α4(+)/(-)α4 interface agonist binding site. Every mutation reduced the percentage of LS-phase function, demonstrating that this site underpins LS-phase function. Oocyte-surface expression of the HSP and each of the LSP constructs was statistically indistinguishable, as measured using β2-subunit-specific [125I]mAb295 labeling. However, maximum function is approximately 5x greater on a "per receptor" basis for unmodified-LSP vs. HSP α4β2-nAChR. Thus, recruitment of the α4(+)/(-)α4 site at higher agonist concentrations appears to augment otherwise-similar function mediated by the pair of α4(+)/(-)β2 sites shared by both isoforms. These studies elucidate the receptor-level differences underlying the differential pharmacology of the two α4β2-nAChR isoforms, and demonstrate that HS vs. LS α4β2-nAChR activity can be selectively manipulated using pharmacological approaches. Since α4β2 nAChR are the predominant neuronal subtype these discoveries likely have significant functional implications, and may provide important insights for drug discovery and development.

  • nicotinic acetylcholine receptors
  • receptor desensitization
  • receptor mutagenesis
  • receptor structure
  • site-directed mutagenesis
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 377 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 377, Issue 2
1 May 2021
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The unique α4(+)/(-)α4 agonist binding site in (α4)3(β)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology vs. the (α4)2(β2)3 subtype
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNeuropharmacology

The unique α4(+)/(-)α4 agonist binding site in (α4)3(β)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology vs. the (α4)2(β2)3 subtype

J. Brek Eaton, Linda M. Lucero, Harrison Stratton, Yongchang Chang, John F. Cooper, Jon M. Lindstrom, Ronald J. Lukas and Paul Whiteaker
Journal of Pharmacology and Experimental Therapeutics November 4, 2013, jpet.113.208389; DOI: https://doi.org/10.1124/jpet.113.208389

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleNeuropharmacology

The unique α4(+)/(-)α4 agonist binding site in (α4)3(β)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology vs. the (α4)2(β2)3 subtype

J. Brek Eaton, Linda M. Lucero, Harrison Stratton, Yongchang Chang, John F. Cooper, Jon M. Lindstrom, Ronald J. Lukas and Paul Whiteaker
Journal of Pharmacology and Experimental Therapeutics November 4, 2013, jpet.113.208389; DOI: https://doi.org/10.1124/jpet.113.208389
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CVN424, a novel GPR6 inverse agonist for Parkinson's disease
  • Methylone Brain Concentrations and Pharmacodynamic Effects
  • Oxysterols and Ethanol
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics